A new study led by researchers at the UCLA Health Jonsson ... evaluated with advanced prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging, suggesting that ...

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

A new study led by researchers at the UCLA Health Jonsson ... evaluated with advanced prostate-specific membrane antigen–positron emission tomography (PSMA-PET) imaging, suggesting that ...

of UCLA Health in Los Angeles, and co-authors in JAMA Network Open. "PSMA-PET/CT continues to evolve as the most accurate imaging method for staging prostate cancer. Our results underline this is ...

US FDA grants fast track designation to Clarity Pharma’s Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer: Sydney, Australia Monday, January 27, 2025, 14:00 Hrs [I ...

Daniel Oguna, a PET CT technologist prepares a patient for a scan procedure at Aga Khan University Hospital, Nairobi. [Photo: Standard] The latest and most advanced scan for evaluation of patients ...

A new UCLA Health Jonsson Comprehensive Cancer Center-led study has revealed that advanced prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging could reveal ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

While prostate cancer is becoming more prevalent among middle-aged and elderly men in China, clinical practice still faces considerable challenges due to the lack of unified guidelines and high-level ...

Prostate cancer stands as the third most common cancer among Malaysian men, with 70 percent of cases diagnosed at advanced ...

A study led by researchers at the UCLA Health Jonsson Comprehensive ... plays a critical role in redefining how prostate cancer is staged. PSMA-PET imaging uses tiny amounts of radioactive ...

PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...